Menopause and estrogen decline increase LDL-C and ApoB.

The transition through menopause and the subsequent decline in endogenous estrogen levels are established drivers of significant changes in lipid profiles, specifically increasing low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ApoB).

Clinical and metabolic evidence

Longitudinal data from the Study of Women's Health Across the Nation (SWAN), which tracked women through the menopausal transition, demonstrates that LDL-C and ApoB levels rise sharply during a four-year window surrounding the final menstrual period. Postmenopausal status is associated with substantially higher LDL-C compared to premenopausal or perimenopausal states, and these elevations are strongly linked to increased subclinical cardiovascular risk markers, such as greater carotid intima-media thickness. Because ApoB is the primary structural protein for LDL and VLDL particles, the reduction in hepatic clearance of these particles directly results in the observed accumulation of both LDL-C and ApoB in the plasma.

Mechanistic explanations

The increase in LDL-C and ApoB is largely mediated by the loss of estrogen’s regulatory influence on hepatic lipid metabolism:

• LDL receptor (LDLR) up-regulation: Estrogen normally enhances the activity of hepatic LDL receptors via estrogen receptor-alpha (ERα) signaling, which activates the SREBP-1 pathway to increase LDLR expression.
• PCSK9 suppression: Estrogen acts through the G protein-coupled estrogen receptor (GPER) to suppress proprotein convertase subtilisin/kexin type 9 (PCSK9). When estrogen declines, PCSK9 levels rise, leading to increased degradation of LDLRs.
• Clearance kinetics: These molecular changes result in a reduced density of functional receptors on the hepatocyte surface. Human kinetic studies show that estrogen can nearly double the fractional catabolic rate (FCR) of LDL; therefore, its decline significantly impairs the liver's ability to clear LDL particles from circulation.

Bottom line

The menopausal transition is definitively associated with increases in LDL-C and ApoB. This shift is primarily driven by the decline in estrogen, which reduces the liver's capacity to clear these particles by decreasing hepatic LDL receptor activity and increasing receptor degradation.